{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T11:07:08Z","timestamp":1693566428345},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T00:00:00Z","timestamp":1447286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s40261-015-0356-9","type":"journal-article","created":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T10:43:02Z","timestamp":1447324982000},"page":"77-86","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Health Resource Utilization in Patients with Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy in China"],"prefix":"10.1007","volume":"36","author":[{"given":"Jing","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,12]]},"reference":[{"issue":"3","key":"356_CR1","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1378\/chest.06-2244","volume":"131","author":"M Soares","year":"2007","unstructured":"Soares M, Darmon M, Salluh JI, Ferreira CG, Thi\u00e9ry G, Schlemmer B, et al. Prognosis of lung cancer patients with life-threatening complications. Chest. 2007;131(3):840\u20136.","journal-title":"Chest"},{"issue":"3","key":"356_CR2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1378\/chest.08-2968","volume":"136","author":"WN William Jr","year":"2009","unstructured":"William WN Jr, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. 2009;136(3):701\u20139.","journal-title":"Chest"},{"issue":"1","key":"356_CR3","first-page":"423","volume":"5","author":"D Qiao","year":"2015","unstructured":"Qiao D, Wang Z, Lu Y, Wen X, Li H, Zhao H. A retrospective study of risk and prognostic factors in relation to lower respiratory tract infection in elderly lung cancer patients. Am J Cancer Res. 2015;5(1):423\u201332.","journal-title":"Am J Cancer Res"},{"issue":"4c","key":"356_CR4","first-page":"2823","volume":"27","author":"I Gkiozos","year":"2007","unstructured":"Gkiozos I, Charpidou A, Syrigos K. Developments in the treatment of non-small cell lung cancer. Anticancer Res. 2007;27(4c):2823\u20137.","journal-title":"Anticancer Res"},{"issue":"11","key":"356_CR5","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.3748\/wjg.v21.i11.3441","volume":"21","author":"J Zhao","year":"2015","unstructured":"Zhao J, Shen H, Hu HG, Huang JJ. Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report. World J Gastroenterol. 2015;21(11):3441\u20136.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"356_CR6","first-page":"171","volume":"13","author":"CG Azzoli","year":"2010","unstructured":"Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer [in Chinese]. Zhongguo Fei Ai Za Zhi. 2010;13(3):171\u201389.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"7","key":"356_CR7","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/annonc\/mdh260","volume":"15","author":"GP Stathopoulos","year":"2004","unstructured":"Stathopoulos GP, Veslemes M, Georgatou N, Antoniou D, Giamboudakis P, Katis K, et al. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol. 2004;15(7):1048\u201355.","journal-title":"Ann Oncol"},{"issue":"3","key":"356_CR8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.lungcan.2009.11.018","volume":"68","author":"C Gridelli","year":"2010","unstructured":"Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone F, et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer. 2010;68(3):319\u201331.","journal-title":"Lung Cancer"},{"issue":"4","key":"356_CR9","first-page":"1365","volume":"30","author":"AK Ganti","year":"2010","unstructured":"Ganti AK, Loberiza FR Jr, Kessinger A. Factors affecting bone marrow toxicity following administration of carboplatin and paclitaxel in patients with non-small cell lung cancer. Anticancer Res. 2010;30(4):1365\u20139.","journal-title":"Anticancer Res"},{"issue":"11","key":"356_CR10","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1158\/1078-0432.CCR-11-2055","volume":"18","author":"KA Gold","year":"2012","unstructured":"Gold KA, Wistuba II, Kim ES. New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res. 2012;18(11):3002\u20137.","journal-title":"Clin Cancer Res"},{"key":"356_CR11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/1477-3163.123972","volume":"12","author":"T Reungwetwattana","year":"2013","unstructured":"Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinog. 2013;12:22.","journal-title":"J Carcinog"},{"issue":"2","key":"356_CR12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1517\/14656566.2013.758714","volume":"14","author":"C Brzezniak","year":"2013","unstructured":"Brzezniak C, Carter CA, Giaccone G. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opin Pharmacother. 2013;14(2):247\u201353.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"356_CR13","first-page":"427","volume":"5","author":"X Cai","year":"2002","unstructured":"Cai X, Chen P, Yin X, Li Q. Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer [in Chinese]. Zhongguo Fei Ai Za Zhi. 2002;5(6):427\u20138.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"2 Pt 1","key":"356_CR14","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1078-0432.690.11.2","volume":"11","author":"GV Scagliotti","year":"2005","unstructured":"Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res. 2005;11(2 Pt 1):690\u20136.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"356_CR15","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2008.20.9114","volume":"27","author":"BH Gr\u00f8nberg","year":"2009","unstructured":"Gr\u00f8nberg BH, Bremnes RM, Fl\u00f8tten O, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(19):3217\u201324.","journal-title":"J Clin Oncol"},{"issue":"9652","key":"356_CR16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","volume":"372","author":"ES Kim","year":"2008","unstructured":"Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809\u201318.","journal-title":"Lancet"},{"key":"356_CR17","doi-asserted-by":"crossref","unstructured":"Sun Z, Wang S, Barnes SR. Understanding congestion in China\u2019s medical market: an incentive structure perspective. Health Policy Plan (Epub 2015 Jul 16).","DOI":"10.1093\/heapol\/czv062"},{"issue":"Suppl 2","key":"356_CR18","first-page":"480","volume":"73","author":"R Kitoh","year":"2015","unstructured":"Kitoh R, Usami S. Ototoxicity of cisplatin [in Japanese]. Nihon Rinsho. 2015;73(Suppl 2):480\u20135.","journal-title":"Nihon Rinsho"},{"issue":"1","key":"356_CR19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0254-6272(14)60062-5","volume":"34","author":"J Zhou","year":"2014","unstructured":"Zhou J, Zhou T, Jiang M, Wang X, Liu Q, Zhan Z, et al. Research progress on synergistic anti-tumor mechanisms of compounds in traditional Chinese medicine. J Tradit Chin Med. 2014;34(1):100\u20135.","journal-title":"J Tradit Chin Med"},{"issue":"6","key":"356_CR20","first-page":"520","volume":"10","author":"J Li","year":"2007","unstructured":"Li J. A clinical comparative study on Traditional Chinese Medicine serving as consolidation treatment in patients with advanced non-small cell lung cancer [in Chinese]. Zhongguo Fei Ai Za Zhi. 2007;10(6):520\u20132.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"22","key":"356_CR21","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/jnci\/djt281","volume":"105","author":"CS Zhu","year":"2013","unstructured":"Zhu CS, Pinsky PF, Kramer BS, Prorok PC, Purdue MP, Berg CD, et al. The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource. J Natl Cancer Inst. 2013;105(22):1684\u201393.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"356_CR22","first-page":"258","volume":"32","author":"ML Zhu","year":"2009","unstructured":"Zhu ML, Cai BQ. Costs of the last hospitalization for patients with acute exacerbation of chronic obstructive pulmonary disease and patients with lung cancer [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi. 2009;32(4):258\u201361.","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0356-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-015-0356-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0356-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T20:53:23Z","timestamp":1692132803000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-015-0356-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["356"],"URL":"https:\/\/doi.org\/10.1007\/s40261-015-0356-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,12]]}}}